Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
Blackstone Inc. (BX)
Last blackstone inc. earnings: 4/23 06:56 am
Check Earnings Report
US:NYSE Investor Relations:
ir.blackstone.com/investors/shareholders/default.aspx
Company Research
Source: Business Wire
The deal affirms Blackstone’s vision of building companies around innovative products to meet unmet patient needs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion.Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expect
Show less
Read more
Impact Snapshot
Event Time:
BX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BX alerts
High impacting Blackstone Inc. news events
Weekly update
A roundup of the hottest topics
BX
News
- IFS or BX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- Medline Indicated to Open 6.9% Higher After Year's Biggest IPO [Yahoo! Finance]Yahoo! Finance
- Blackstone (NYSE:BX) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $164.00 to $185.00. They now have a "buy" rating on the stock.MarketBeat
- Blackstone and Phoenix Financial Announce PartnershipBusiness Wire
- KKR Stock: Is KKR Underperforming the Financial Sector? [Yahoo! Finance]Yahoo! Finance
BX
Earnings
- 10/24/25 - Miss
BX
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 11/14/25 - Form 13F-HR
- BX's page on the SEC website